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Background: Evidence-based guidelines from the World Health Organization (WHO) have recommended a high (80%)
fraction of inspired oxygen (FiO2) to reduce surgical site infection in adult surgical patients undergoing general anaes-
thesia with tracheal intubation. However, there is ongoing debate over the safety of high FiO2. We performed a sys-
tematic review to define the relative risk of clinically relevant adverse events (AE) associated with high FiO2.
Methods: We reviewed potentially relevant articles from the WHO review supporting the recommendation, including an
updated (July 2018) search of EMBASE and PubMed for randomised and non-randomised controlled studies reporting AE in
surgical patients receiving 80% FiO2 compared with 30e35% FiO2. We assessed study quality and performedmeta-analyses
of risk ratios (RR) comparing 80% FiO2 against 30e35% for major complications, mortality, and intensive care admission.
Results:We included 17 moderateegood quality trials and two non-randomised studies with serious-critical risk of bias.
No evidence of harm with high FiO2 was found for major AE in the meta-analysis of randomised trials: atelectasis RR 0.91
[95% confidence interval (CI) 0.59e1.42); cardiovascular events RR 0.90 (95% CI 0.32e2.54); intensive care admission RR
0.93 (95% CI 0.7e1.12); and death during the trial RR 0.49 (95% CI 0.17e1.37). One non-randomised study reported that high
FiO2 was associated with major respiratory AE [RR 1.99 (95% CI 1.72e2.31)].
Conclusions: No definite signal of harm with 80% FiO2 in adult surgical patients undergoing general anaesthesia was
demonstrated and there is little evidence on safety-related issues to discourage its use in this population.l decision: 8 November 2018; Accepted: 8 November 2018
World Health Organization. Published by Elsevier Ltd. on behalf of British Journal of Anaesthesia.
issions, please email: permissions@elsevier.com
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surgical wound infectionEditor’s key points
 While guidelines from the WHO recommend a high
FiO2 to reduce surgical site infection in adult surgical
patients undergoing general anaesthesia, there is
ongoing debate over its safety.
 This systematic review and meta-analysis of 17 RCTs
did not find robust evidence that perioperative 80% FiO2
is associated with a significant risk of harm compared
with 30e35% oxygenation.
 The available evidence indicated that high FiO2 has no
significant deleterious effect on hard outcomes, such as
ICU admissions and mortality.
 Future studies should focus on adverse events as the
main predefined outcome with rigorous monitoring
and transparent reporting.In 2016, the WHO issued a set of recommendations on
practical measures to prevent surgical site infection (SSI).1,2
As part of the WHO guideline development process, a sys-
tematic review and meta-analyses were conducted on the
effect of a high fraction of inspired oxygen (FiO2) on SSI. The
reviewers reported that 80% FiO2 showed a significant
benefit in reducing SSI when compared with a standard FiO2
of 30% or 35% in intubated patients without any evidence of
harm.3 Nevertheless, concerns regarding the potential
harmful effects of high FiO2 have generated intense discus-
sion on the benefit vs harm balance of high FiO2 in pre-
venting SSI, and a recent meta-analysis found that liberal
oxygen use in acutely ill patients was associated with
increased mortality.4e7
The trade-off between the benefits and risks of high FiO2
continue to be debated in the scientific literature, with
concerns raised regarding increased risk of respiratory and
cardiovascular adverse events (AE) and mortality.8e10 One
specific criticism was that the WHO systematic review and
guidelines had failed to adequately analyse the potential
negative effects of high FiO2.
8e10 These concerns about the
harms of high FiO2 have been countered by the observation
that the studies cited were based on evidence from animal
studies and clinical settings differing from perioperative
care.11 Nevertheless, this ongoing debate highlighted the
urgent need for a thorough evaluation of studies examining
AE associated with high FiO2 in patients undergoing surgery.
We conducted a systematic review aimed specifically at
extracting AE data from randomised trials (including those
reported in the accompanying efficacy review) and non-
randomised studies related to the perioperative adminis-
tration of 80% FiO2 (I) compared with 30e35% (C) in patients
undergoing surgery (P) for the purpose of reducing the risk of
SSI (O).12Methods
Study selection criteria
Our inclusion criteria for studies followed those of the original
WHO guidelines1 by using the same intervention and compar-
ators as the efficacy review, but with the additional parameter
of the inclusion of non-randomised studies. We selected rele-
vant studies that had: (i) between-group comparisons, either of
a randomised or a non-randomised design; (ii) patients of any
age undergoing any type of surgical procedure; and (iii) peri-
operative administration of high FiO2 (80%) vs a control or
comparator group, where the comparatorwas the perioperative
administration of standard FiO2 (30e35%).Search strategy
We identified potentially relevant studies from several sour-
ces, starting with a new database search with no restriction on
study design or outcome. This specific search focusing on ar-
ticles with AE terms is fully reported in Supplementary
Table S1 and was first conducted on June 5, 2017 based on
free-text and the indexing terms used in PubMed and EMBASE.
To capture all relevant new articles, we set up automated
notifications from PubMed (most recent update, July 2018). We
then went on to evaluate all the trials included in the accom-
panying efficacy review.12 As there may have been studies of a
non-randomised design or trials that had not reported on SSIs
relevant to the efficacy endpoint, but could contribute AE data,
we also checked all full-text articles classified as ‘wrong
design’ or ‘wrong outcome’ in the efficacy review. Finally, we
checked reference lists of included articles and systematic
reviews and consulted with experts from WHO in the event
that they might be aware of other potentially relevant articles
that specifically reported AE associated with high FiO2.Study selection
Two reviewers (Y.K.L. and K.M.) independently screened titles
and abstracts of retrieved references for relevant studies based
on population, intervention, and comparator. At this time, we
did not exclude articles based on the absence of AE reporting
in the abstract, as these data may not have been mentioned,
even if present in the full article. We then retrieved full-text
versions of these articles and both reviewers further checked
these against the inclusion criteria.Outcomes of interest
We examined the effect of high FiO2 on the following pre-
specified adverse outcomes of interest: (i) mortality; (ii)
ischaemic vascular events affecting coronary and cerebral
circulation; (iii) respiratory AE (e.g. respiratory failure, acute
respiratory distress syndrome, number of ventilator days, and
lung complications, for example, pneumonia or atelectasis, re-
intubation or prolonged intubation); and (iv) length of hospital
Safety of high oxygen during surgery - 313stay. In addition, we used a hypothesis generating/scoping
approach to capture any new or unexpected serious AE that
may have been reported.Data extraction
Two reviewers (A.S. and A.P., or Y.K.L. and K.M.) indepen-
dently extracted data from all included studies onto a pre-
formatted form. To avoid a bias towards the null that could
arise from attempting to evaluate AE in patients who had
never received the intervention, participant numbers were
extracted based on the study population that had received the
assigned intervention and where outcomes had been
measured.Assessment of study validity
The risk of bias of the RCTs included in the effectiveness
reviewwas assessed by two authors (J.S. and S.W.),12 whereas
another two pairs of reviewers (A.S. and A.P., and Y.K.L. and
K.M.) were involved in the independent assessment of the
validity of included AE studies using the CochraneRecords idenﬁed th
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Fig 1. Flowchart of study selection.Collaboration tools for assessing the risk of bias in non-
randomised studies of interventions (ROBINS-I),13,14 and
components from the specific McMaster Harms tool for AE
trials.15 We focused on whether AE were pre-specified, the
degree of rigour of postoperativemonitoring, and the amount
of reported detail on AE. We aimed to assess publication bias
using a funnel plot if there were more than 10 studies in a
meta-analysis and the absence of significant statistical
heterogeneity.16
For the overall body of evidence, we used the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) methodology (GRADE Pro software; http://gradepro.
org/).Statistical analysis
We focused our analysis on the measure of relative effect
measure between intervention and control to minimise the
impact of the fact that themonitoring,measurement, and case
definition of participants and their AE were often ad hoc or post
hoc in studies, thus leading to inconsistencies in absolute
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314 - Mattishent et al.study arms were measured in the same (good or bad) way, the
relative effect should be a more consistent measure that al-
lows pooling and a comparison between trials. This is because
any misclassification is non-differential within that study and
any relative difference between study arms is maintained.
Meta-analyses of the risk of AE were conducted using Review
Manager v 5.3 (Nordic Cochrane Centre, Copenhagen,
Denmark) if there were quantitative data of sufficient quantity
and similarity. Depending on the reported effectmeasures and
extent of statistical heterogeneity (assessed using the I2 sta-
tistic), we planned to pool risk ratios (RR) or mean differences
with a fixed effects model if there was an absence of hetero-
geneity and random effects models when substantial hetero-
geneity (50% or above) was detected.17,18 If the data were
sparse or clinically heterogeneous, we aimed to report a
narrative synthesis.Results
We identified 32 full-text articles, and subsequently excluded
five reports (Fig. 1).19e49 One article was a symposium report
that contained atelectasis data from another trial,22 and four
trials (one has already been retracted) had discrepant findings
in the statistical analysis. We have not included these latter
studies pending a request for further clarification.37,38,48,49 A
total of 27 studies were included in the final analysis. These
consisted of two non-randomised studies43,46 and 17 separate
RCTs with eight post hoc or subgroup analyses.19e36,39e42,44,45,47
Several trials had overlapping or multiple reports. Outcome
data of participants in the RCT by Greif and Sessler32 were also
mentioned in other publications (i.e. data on imaging for pul-
monary complications from Akc¸a and colleagues,19 on atel-
ectasis from Horn,22 and on long-term mortality from
Podolyak and colleagues26). Long-termmortality from the trial
of Kurz and colleagues23 was reported in the article byTable 1 Study characteristics of non-randomised studies. IQR, inter-
Study (and year) Study design, setting,
type of surgery
Patient characteri
Kurz and
colleagues46
(2018)
Two-weekly alternating
intervention study in
operating rooms in the
Cleveland Clinic, USA
Major intestinal surgery
January 2013 to
March 2016
Total number of
patients: 5749
30% O2: 2853
80% O2: 2896
Mean age (SD):
30% O2: 52 yr (17
80% O2: 52 yr (17
% Male: 48 in
both groups
Staehr-Rye and
colleagues43
(2017)
Retrospective cohort
Massachusetts General
Hospital and two
community hospitals, USA
Non-cardiothoracic surgery
January 2007e August 2014
Total number: 739
Mean age
30% O2: 55 yr
80% O2: 57 yr
% Male
30% O2: 47
80% O2: 44
Excluded: age <1
previous surgery
within the last 4
missing informa
in any of the var
used in the prim
regression modePodolyak and colleagues.26 The Meyhoff and colleagues34
PROXI trial was further described in several subsequent re-
ports: Fonnes and colleagues21 reported on cerebrovascular
outcomes; Meyhoff and colleagues24 on long-term mortality;
Meyhoff and colleagues25 on cancer; Staehr and colleagues28
on a subgroup of patients with obesity; and Staehr27 on a
subgroup with ovarian cancer at a single centre.28 The key
features of the RCTs are fully reported in the accompanying
article related to the systematic review on effectiveness.12 To
avoid duplication, Table 1 shows the baseline characteristics
of the non-randomised studies and Supplementary Table S2
reports full details on outcomes and monitoring of AE across
all studies.RCTs
Sample sizes ranged from 30 to 2050 patients with a wide
range of international locations. Age groups were wide-
ranging between trials, but comparable between intervention
and comparator groups. Of the 17 original RCTs, a broad range
of surgical procedures was studied. These included colorectal
surgery (n¼5), appendectomy (n¼2), Caesarean section (n¼5),
laparotomy (n¼1), orthopaedic surgery for fractures (n¼1), and
mixed surgery (n¼3). Most trials were conducted in intubated
patients; five trials were performed in participants who were
non-intubated or given regional anaesthesia.30,31,39,42,45Non-randomised studies
Two non-randomised studies were identified.43,46 The first
was a retrospective cohort study that analysed 73 922 intu-
bated patients undergoing non-cardiothoracic surgery in a
large university teaching hospital and two community hospi-
tals in the USA.43,46 Patients were divided into five groups
based on a quintile of the median FiO2 between the time of
intubation and extubation. As this was a retrospective non-quartile range; SD, standard deviation
stics Intervention Control
)
)
Notices and signs on
each anaesthesia
machine with an
alert system if FiO2
<70% or >90%
Median FiO2 delivered
was 80% (IQR 77e82%)
Enough oxygen to
achieve oxygen
saturations of >95%
in addition to an
alert system if
FiO2 >35%
Median FiO2 delivered
was 39% (IQR 35e52%)
22
8 yr,
weeks,
tion
iables
ary
l
Five patient groups,
of which Group 1 had
received median 30%
O2 and Group 5
median 80% O2
Quintiles of groups
defined by median
intraoperative FiO2
between intubation
and extubation
Non-randomised study
with no protocolised
intervention before
start of study
Duration of anaesthetic
Group 1: median 155 min
Group 5: median 89 min
Safety of high oxygen during surgery - 315randomised study, there was no description of whether pre-
operative, perioperative, and postoperative interventionswere
protocolised or standardised among the patient groups. The
second study was a quality improvement project that evalu-
ated outcomes in 5749 patients undergoing major intestinal
surgery in a US single centre where operating rooms alter-
nated between 30% and 80% FiO2.
23 The inspired fraction was
changed every 2 weeks on a non-randomised basis; clinicians
were not blinded to the FiO2 received by the patient. As this
was not a prospective RCT with a pre-specified follow-up,
clinical outcomes were obtained from the clinical registry and
hospital billing system.Study quality (risk of bias)
The internal validity of the RCTs was considered to be
moderateegood overall; details are fully reported in the
accompanying effectiveness review.12 In general, there were
no major areas with consistently high risk of bias,23 although
one trial was at risk of selective outcome reporting, while
another was affected by lack of blinding.39 However, our re-
view included several subgroup or post hoc analyses of
completed trials, which may be of lower quality and at greater
risk of bias than the original publications. The definitions,
measurement, and reporting of pulmonary and cardiovascular
AE were clearly specified in only two trials; these two studies
were judged as adequate overall.34,35 All the other trials were
judged to have inadequate areas in their measurement and
reporting of AE data (Table 2).
In particular, the study by Staehr-Rye and colleagues43
was considered to be at critical risk of bias based on several
of the ROBINS-I criteria (Table 3). Although a large set of
variables was used in the regression model, these were
applied in a blanket manner to all outcomes, rather than
tailored to the specific outcome as stipulated in the ROBINS-ITable 2Adequacy of collection, measurement, and reporting of adver
scale)
Study (and year) Adequate specification
or definition of
pulmonary
or cerebrovascular
adverse events
Adeq
and
pulm
cereb
mon
Belda and colleagues20 (2005) Inadequate Inad
Bickel and colleagues29 (2011) Inadequate Inad
Chen and colleagues44 (2013) Inadequate Inad
Duggal and colleagues30 (2013) Inadequate Inad
Fariba and colleagues45 (2016) Inadequate Inad
Gardella and colleagues31 (2008) Inadequate Inad
Greif and Sessler32 (2000) Adequate for
pulmonary
Inad
Kurz and colleagues23 (2015) Inadequate Inad
Kurz and colleagues46 (2018) Inadequate Inad
Mayzler and colleagues33 (2005) Inadequate Inad
Meyhoff and colleagues34 (2009) Adequate Adeq
Myles and colleagues35 (2007) Adequate Adeq
Pryor and colleagues36 (2004) Inadequate Inad
Scifres and colleagues39 (2011) Inadequate Inad
Staehr-Rye and colleagues43 (2017) Inadequate Inad
Stall and colleagues40 (2013) Inadequate Inad
Thibon and colleagues41 (2012) Inadequate Inad
Wasnik and colleagues47 (2015) Inadequate Inad
Williams and colleagues42 (2013) Inadequate Inadcriteria.14 We considered it highly unlikely that the relevant
adjustment of confounding variables for pneumonia would
be the same as those for pulmonary oedema, and even less
likely for wound dehiscence or stroke (all of which would be
affected by completely different factors). At baseline, there
was an imbalance between Group 1 and Group 5 in the pro-
portion of patients with an ASA physical status 3 and above
(i.e. 25% in Group 1 compared with 39% in Group 5). The type
of surgery also differed with 16% vs 40% having general sur-
gery in Group 1 and Group 5, respectively. This raises the
possibility of other residual confounding causing bias (e.g.
co-morbid conditions such as cancer or congestive heart
failure). Other major areas of concern were the absence of
blinding for outcome assessors, lack of specification of how
and when AE were coded, and the exclusion of more than 35
000 potentially eligible study participants, because of missing
information on single covariates such as height, BMI, age and
multi-morbidity score. Co-interventions (such as wound care
and antibiotics) were not equally delivered between groups
(e.g. median duration of anaesthesia was 155 min in the
quintile that received low FiO2 compared with 89 min in the
quintile that received high FiO2). Finally, the protocol-
specified outcome of SSI was not reported in the study and
the analysis appears to have been changed to the outcome of
‘wound dehiscence’ instead.
We judged the alternating intervention study by Kurz and
colleagues46 to be at serious risk of bias (Table 3) according to
the ROBINS-I scale. Major weaknesses included lack of blind-
ing and the use of registry and billing data, rather than
investigator-led outcome ascertainment. We identified devia-
tion from the intervention in the 30% FiO2 group where the
median inspired fractionwas 39%, with an inter-quartile range
of 35e52%, thus indicating that 25% of patients were receiving
>52% FiO2. This would have reduced the ability of the trial to
differentiate between high and low FiO2. Finally, we noted thatse events data (adapted from components of theMcHarm quality
uate method
frequency of
onary or
rovascular
itoring
Independent
data safety
monitoring
Completeness
of follow-up
Comprehensive
reporting of
adverse events
equate Adequate Adequate Inadequate
equate Inadequate Adequate Inadequate
equate Inadequate Adequate Inadequate
equate Inadequate Inadequate Inadequate
equate Inadequate Inadequate Inadequate
equate Inadequate Adequate Inadequate
equate Inadequate Adequate Adequate for
pulmonary
equate Inadequate Adequate Inadequate
equate Inadequate Inadequate Adequate
equate Adequate Adequate Inadequate
uate Adequate Adequate Adequate
uate Adequate Adequate Adequate
equate Inadequate Adequate Inadequate
equate Inadequate Adequate Inadequate
equate Inadequate Inadequate Adequate
equate Adequate Adequate Inadequate
equate Inadequate Adequate Inadequate
equate Inadequate Inadequate Inadequate
equate Inadequate Adequate Inadequate
Table 3 Assessment of study validity of non-randomised studies. ROBINS-I, risk of bias in non-randomised studies of interventions
Study
(and year)
Bias as a
result of
confounding
Bias in
selection
Bias in
classification
of intervention
Bias as a result of
deviation from
intervention
Bias as a
result of
missing
data
Bias in
measurement
of outcomes
Bias in
selection of
the reported
results
Overall
ROBINS-I
judgment
Kurz and
colleagues46
(2018)
Moderate Low Low Serious Moderate Serious Serious Serious
Staehr-Rye43
(2017)
Critical Low Serious Serious Critical Critical Serious Critical
316 - Mattishent et al.the protocol had a pre-specified SSI composite outcome, but
this had been changed in the study to a composite of mortality
and surgical infection.Results of individual studies
We listed the number of study participants that received the
assigned intervention (per protocol) and had analysable
outcome data (Table 4). Included studies reported on the
following AE: atelectasis; pneumonia; respiratory complica-
tions and serious AE that included respiratory failure, pneu-
mothorax, cough, and respiratory difficulty; ICU admission;
cardiovascular events; thromboembolic events; death (short-
and long-term); and length of hospital stay. Overall, no evi-
dence of statistically significant harm was observed in any of
the adverse outcomes. However, AE data were sparsely and
inconsistently reported (Table 4).Outcomes: atelectasis
Three studies reported on atelectasis with 219/1932 events in
the high FiO2 arm and 255/1966 events in the low FiO2 arm
(Fig. 2).32,34,35 Overall, high FiO2 was not associated with an
increased risk of atelectasis {pooled RR 0.91 [95% confidence
interval (CI) 0.59e1.42]}. There was considerable heterogeneity
in the analysis (I2¼85%).Outcomes: pneumonia
Three trials reported on pneumonia with 57/1712 events in the
high FiO2 arm and 75/1746 events in the low FiO2 arm (Fig. 2).
The pooled estimates did not demonstrate a significant asso-
ciation between high FiO2 and pneumonia [overall pooled RR
0.78 (95% CI 0.55e1.09)].21,35,44 There was mild heterogeneity
(I2¼29%). In contrast, the observational study reported an
adjusted odds ratio (OR) of 1.72 (95% CI 1.30e2.28) for pneu-
monia in the high FiO2 group.Outcomes: composite measure of respiratory AE
Two studies reported on composite measures of respiratory
AE. Myles and colleagues35 described respiratory complica-
tions (pneumonia, atelectasis, pneumothorax, and pulmonary
embolism), and Meyhoff and colleagues34 mentioned serious
respiratory AE, but with no further definition. However, the
composite data were not pooled because of variations in case
definitions when constructing the composite. We did not
identify any significant harm related to high FiO2 in either
study. In contrast, the observational study reported anadjusted OR of 1.99 (95% CI 1.72e2.31) for major respiratory
complications in the high FiO2 group.Outcomes: ICU admission
Five studies reported on ICU admission with 190/2165 events
in the high FiO2 arm and 208/2189 events in the low FiO2 arm
(Fig. 2).20,32,34e36 High FiO2 was not associated with an
increased likelihood of ICU admission [RR 0.93 (95% CI
0.77e1.12)]. Low heterogeneity was observed in the analysis
(I2¼3%). In contrast, the observational study by Staehr-Rye
and colleagues43 reported an adjusted OR of 1.64 (95% CI
1.38e1.95) for ICU admission in the high FiO2 group. However,
we noted that the raw or crude OR for ICU admission was
actually 0.94 (95% CI 0.82e1.08). Notably, the statistical
adjustment appears to have converted a non-significant
decrease in risk to a statistically significantly association in
increased risk with high FiO2.Outcomes: cardiovascular AE
Three studies reported on cardiovascular AE, consisting of
acute coronary syndrome and myocardial infarction with 25/
1705 events in the high FiO2 arm and 25/1744 events in the low
FiO2 arm (Fig. 2).
21,35,44 Overall, high FiO2 was not associated
with cardiovascular AE [pooled RR 0.90 (95% CI 0.32e2.54)]. One
of the trials had sparse raw data and there was significant
heterogeneity (I2¼58%). We conducted a sensitivity analysis
including myocardial infarction rather than acute coronary
syndrome as the outcome measure from the Fonnes and col-
leagues21 study, and this yielded an overall pooled RR of 0.94
(95% CI 0.28e3.21). Similarly, there were no significant asso-
ciations reported for myocardial infarction and stroke in the
observational study. However, our analysis of the raw or crude
OR found that high FiO2 was associated with a reduced risk of
stroke [OR 0.52 (95% CI 0.38e0.71)], but the regression model
subsequently generated an adjusted OR of 0.90 (95% CI
0.59e1.37) for stroke in the high FiO2 group.Outcomes: thromboembolic events
Two studies reported adjusted estimates on thromboembolic
events, one on pulmonary embolism and one on any throm-
boembolic event (Fig. 2).21,35 There was no significant associ-
ation between high FiO2 and thromboembolic events [pooled
RR 0.89 (95% CI 0.28e2.91)], but there was heterogeneity
(I2¼74%).
Table 4Matrix of adverse events. Outcomes reported by the included trials showing numbers of patients affected by adverse events/total number, according to intervention of high (80%)
FiO2 compared with low (30e35%) FiO2. ACS, acute coronary syndrome; NR, not reported; OR, odds ratio; PE, pulmonary embolism; SAE, serious adverse event; SD, standard deviation.
Study (and year) Number of
patients
Atelectasis Pneumonia Other respiratory
adverse events
Cardiovascular
adverse events
ICU admission Length of stay
[days (SD)]
Mortality (n) Other (e.g. cancer,
stroke, embolism,
SAE)
Belda and
colleagues20
(2005)
Low FiO2¼143*
High FiO2¼148*
NR NR NR NR Low FiO2: 5/143
High FiO2: 4/148
Low FiO2: 10.5
(4.4) High
FiO2: 11.7 (7.0)
Low FiO2: 2/143
High FiO2: 0/148
NR
Bickel and
colleagues29
(2011)
Low FiO2¼103
High FiO2¼107
NR NR NR NR NR Low FiO2: 2.9
High FiO2: 2.5
NR NR
Chen and
colleagues44
(2013)
Low FiO2¼30
High FiO2¼30
NR Low FiO2: 1/30
High FiO2: 1/30
NR Low FiO2: 3/30
High FiO2: 1/30
NR NR Low FiO2: 0/30
High FiO2: 030
NR
Duggal and
colleagues30
(2013)
Low FiO2¼415
High FiO2¼416
NR NR NR NR NR NR NR NR
Fariba and
colleagues45
(2016)
NR NR NR NR NR NR NR NR NR
Gardella and
colleagues31
(2008)
Low FiO2¼74*
High FiO2¼69*
NR NR NR NR NR Low FiO2: 3
(range 2e6)
High FiO2: 3
(range 2e5)
NR NR
Greif and Sessler32
(2000)
Low FiO2¼250
High FiO2¼250
Low FiO2: 78/250
High FiO2: 90/250
NR NR NR Low FiO2: 12/250
High FiO2: 5/250
Low FiO2: 11.9
High FiO2: 12.2
Low FiO2: 6/250
High FiO2: 1/250
NR
Mayzler and
colleagues33
(2005)
Low FiO2¼19
High FiO2¼19
NR NR NR NR NR NR NR NR
Meyhoff and
colleagues34
(2009)
Low FiO2¼685*
High FiO2¼701*
Low FiO2: 50/685
High FiO2: 54/701
Low FiO2: 44/685
High FiO2: 41/701
Respiratory SAE Low
FiO2: 25/685 High
FiO2: 27/701
Respiratory failure
(Low FiO2: 31/685
High FiO2: 38/701)
NR Low FiO2: 44/685
High FiO2: 30/701
NR Low FiO2: 20/685
High FiO2: 30/701
Any SAE Low
FiO2: 154/685
High FiO2: 165/701
Circulatory SAE
Low FiO2: 20/685;
High FiO2: 24/701
Myles and
colleagues35
(2007)
Low FiO2¼1015*
High FiO2¼997*
Low FiO2: 127
High FiO2: 75
Low FiO2: 30
High FiO2: 15
Any pulmonary
complication
Low FiO2: 132
High FiO2: 78
Pneumothorax
(Low FiO2: 3
High FiO2: 1)
Low FiO2: 13
High FiO2: 7
Adjusted OR
myocardial
infarction 0.58
(95% CI 0.22e1.50)
Low FiO2: 140
High FiO2: 122
Low FiO2: 7.0
High FiO2: 7.1
Low FiO2: 9
High FiO2: 3
Adjusted OR
0.33 (95%
CI 0.09e1.22)
Thromboembolism
Low FiO2: 10; High
FiO2: 16 Adjusted
OR 1.60 (95%
CI 0.72e3.55)
Stroke Low FiO2: 1;
High FiO2: 1
Pryor and
colleagues36
(2004)
35%¼ 80*
High FiO2¼85
NR NR NR NR 35: 7/80
High FiO2: 9/85
35%: 6.4
High FiO2: 8.3
35%: 1/80
High FiO2: 0/85
NR
Scifres and
colleagues39
(2011)
Low FiO2¼297*
High FiO2¼288*
NR NR NR NR NR NR NR NR
Stall and
colleagues40
(2013)
Low FiO2¼116*
High FiO2¼119*
NR NR NR NR NR Low FiO2: 2.8
High FiO2: 3.5
NR NR
Thibon and
colleagues41
(2012)
Low FiO2¼208
High FiO2¼226
NR NR NR NR NR NR NR Hypotension
Low FiO2: 0/208
High FiO2: 3/226
Williams42 (2013) Low FiO2¼83*
High FiO2¼77*
NR NR NR NR NR NR NR NR
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Table 4 Continued
Study (and year) Number of
patients
Atelectasis Pneumonia Other respiratory
adverse events
Cardiovascular
adverse events
ICU admission Length of stay
[days (SD)]
Mortality (n) Other (e.g. cancer,
stroke, embolism,
SAE)
Akc¸a and
colleagues19
(1999) [subgroup
Greif and
Sessler32 (2004)]
Low FiO2¼14
High FiO2¼16
CT-determined
atelectasis
Low FiO2: 9/14
High FiO2: 15/16
NR Cough/respiratory
difficulty
Low FiO2: 3/14
High FiO2: 5/16
NR NR NR NR NR
Fonnes and
colleagues21
(2016)
Low FiO2¼699
High FiO2¼678
NR NR NR Adjusted
hazard ratio:
Acute coronary
syndrome
1.96 (95%
CI 0.86e4.48)
Myocardial
Infarction
2.58 (95%
CI 0.97e6.88)
NR NR ACS/death
Low FiO2: 190/699
High FiO2: 219/678
Pulmonary embolism
adjusted hazard
ratio: 0.48 (95%
CI 0.19e1.19)
Horn22 (2002) [data
from Akc¸a and
colleagues19
(1999)&Greif and
Sessler32 (2004)]
Low FiO2¼14
High FiO2¼16
Low FiO2: 5
High FiO2: 7
NR NR NR NR NR NR NR
Kurz and
colleagues23
(2015)
Low FiO2¼270*
High FiO2¼285*
NR NR NR NR NR Low FiO2: 7.7
(4.6)
High FiO2:
8.8 (5.4)
Low FiO2: 1/270
High FiO2: 0/285
Major complications
Low FiO2: 34/270
High FiO2: 42/285
Meyhoff and
colleagues24
(2012)
Low FiO2¼701*
High FiO2¼685*
NR NR NR NR NR NR Adjusted hazard
ratio 1.31 (95%
CI 1.03e1.55)
NR
Meyhoff and
colleagues25
(2014)
Low FiO2¼699*
High FiO2¼678*
NR NR NR NR NR NR Adjusted hazard
ratio 1.29 (95%
CI 1.05e1.58)
New cancer diagnosis
Low FiO2: 30/699
High FiO2: 25/678
Podolyak26 (2016)
[Kurz and
colleagues23 and
Greif and
Sessler32 (2004)
together]
Low FiO2¼459*
High FiO2¼468*
NR NR NR NR NR NR Hazard ratio 0.93
(95% CI 0.72e1.20)
NR
Staehr and
colleagues28
(2011)
Low FiO2¼111*
High FiO2¼102*
Low FiO2: 7
High FiO2: 9
Low FiO2: 5
High FiO2: 6
Respiratory failure
Low FiO2: 5/111
High FiO2: 8/102
Low FiO2: 9/111
High FiO2: 11/102
Low FiO2: 5 days
High FiO2: 6 days
Low FiO2: 3/111
High FiO2: 1/102
SAE
Low FiO2: 22/111
High FiO2: 22/102
Staehr and
colleagues27
(2012)
Low FiO2¼15
High FiO2¼20
Low FiO2: 2/15
High FiO2: 5/20
NR NR NR NR NR NR NR
Wasnik and
colleagues47
(2015)
Low FiO2¼32
High FiO2¼32
NR NR NR NR NR Low FiO2: 9.84
(3.68)
High FiO2:
7.37 (3.57)
NR NR
* Refers to participant numbers that actually received the intervention and were finally available for inclusion in the primary analysis and not the numbers originally randomly assigned to the intervention
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Fig 2. Pooled risk ratio for adverse events. CI, confidence interval; M-H, Mantel-Haenszel.
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Fig 3. Pooled risk ratio for death, including short- and long-term follow-up.
320 - Mattishent et al.Outcomes: short-term death
Seven trials reported on death in the short-term on follow-up
as specified for the original trial period with 34/2480 events in
the high FiO2 arm and 39/2489 events in the low FiO2 arm
(Fig. 3).20,23,32,34e36,44 High FiO2 was associated with a reduced
risk of death, but CIs were wide and included unity [pooled RR
0.49 (95% CI 0.17e1.37)]. There was some evidence of hetero-
geneity (I2¼50%). The observational study by Staehr-Rye and
colleagues43 reported an adjusted OR of 2.09 (95% CI 0.81e5.43)
for mortality within 7 days in the high FiO2 group.Outcomes: inclusion of long-term death data in
combination with short-term
As there were studies with adjusted data for post hoc long-term
follow-up, we constructed a forest plot to show the adjusted
data separately from the analysis based on raw data (Fig. 3).
When the long-term data (with additional follow-up after
original study period) was pooled with the two studies that
reported only short-term follow-up, high FiO2 was not signif-
icantly associated with a long-term risk of death [pooled RR0.96 (95% CI 0.65e1.42)], with evidence of heterogeneity
(I2¼55%).20,24,26,35,36 In contrast, the observational study by
Staehr-Rye and colleagues43 reported an adjusted OR of 1.97
(95% CI 1.30e2.99) for mortality within 30 days in the high FiO2
group. The alternating intervention study by Kurz and col-
leagues46 also reported an adjusted RR of 1.97 (95% CI
0.71e5.47) for 30 day mortality associated with high FiO2.Outcomes: length of stay
Ten studies reported on length of stay in hospital (Table 4).
However, the format of the data was inconsistent andwewere
unable to identify any clear trends in the results to indicate
clinically important differences in length of stay between the
high FiO2 and control groups.Other outcomes
We identified a number of post hoc and subgroup analyses that
focused on single centres or single outcomes that were not
suitable for inclusion in the meta-analysis. Meyhoff and col-
leagues25 described a possible association (after a median of
Safety of high oxygen during surgery - 3213.9 yr follow-up) between high FiO2 and poorer cancer-free
survival, but the study was unable to ascertain the cause of
the excess mortality. These findings led to another post hoc
analysis conducted by Podolyak and colleagues,26 which
concluded that unlike the PROXI trial, the two trials by Greif
and Sessler32 and Kurz and colleagues23 did not show any
association between high FiO2 and mortality, either overall or
in those with cancer. Another article reported on the lack of
association between obesity and pulmonary complications in
participants of the PROXI trial.28Subgroup and sensitivity analyses
Four trials (one already retracted) are awaiting further
assessment and clarification.37,38,48,49 Of note, a sensitivity
analysis based on these data did not lead to any change in
direction of effect or statistical significance for AE. There were
too few studies included in any particular meta-analysis to
perform a meaningful analysis according to subgroups or
anaesthetic techniques. For instance, all trials in the initial
meta-analysis were conducted in participants who were
intubated and, therefore, we could not separately evaluate AE
in those with regional anaesthesia. We were also unable to
construct multiple subgroups based on different types of sur-
gery, as the included studies consisted mainly of laparotomies
or a mix of major procedures.Discussion
Our analysis of 17 RCTs did not find any robust or consistent
evidence that perioperative administration of 80% FiO2 is
associated with a significant risk of harm compared with
30e35% oxygenation. The available evidence demonstrates
that high FiO2 had no significant deleterious effect on hard
outcomes, such as ICU admissions and mortality. No definite
signal of harm was identified for all other trial-related AE,
particularly pulmonary and cardiovascular outcomes,
although these findings were only backed by a low quality of
evidence (GRADE, Supplementary Table S3). This stems from
the small number of events and lack of statistical power,
which means that the analysis of RCTs cannot completely
exclude an increased risk of AE.
Although the non-randomised studies had much larger
sample sizes, there were potential biases from the handling of
confounders, missing data, and absence of blinding in
outcome ascertainment. This was a particular concern in the
study by Staehr-Rye and colleagues,43 with an instability in
results that arose after adjustment for confounding. For
instance a significant beneficial association of high FiO2 in
reducing stroke risk was rendered non-significant after
adjustment. Unexpectedly, the possibly beneficial associa-
tions of high FiO2 in reducing ICU admission and wound
dehiscence in this study had complete changes in direction of
effect after adjustment (resulting in statistically significant
harm for ICU admission with high FiO2).
It is also not clear why certain patients were given higher
concentrations of oxygen than others in the non-randomised
studies. Those who received the highest concentrations in
the study by Staehr-Rye and colleagues43 were more likely to
be in a higher ASA class, to have undergone general surgery,
and had shorter anaesthetic durations. Protopathic bias is one
possibility whereby higher concentrations of oxygen were
initiated in managing patients with early or emerging (but not
yet fully diagnosed) cardiorespiratory signs and symptoms.Similarly, confounding by indication occurs if patients with a
past history of pneumonia or congestive heart failure/pulmo-
nary oedema are treated with higher concentrations of oxy-
gen. The adjusted models in the non-randomised studies do
not address these two potential sources of bias.
We deliberately chose a focused set of inclusion and
exclusion criteria for this systematic review to maintain direct
relevance and applicability to published guidelines (i.e. the
patient group, intervention, and comparator should be the
same as evaluated for the development of the WHO recom-
mendation). Otherwise, it would have been impossible to tell
whether the recorded AE were as a result of the underlying
disease, the surgical procedure itself, or the intervention and
its comparator. In pharmaceutical evaluations, patients typi-
cally receive a single drug at the prescribed time and it is
relatively easy to investigate a causal relationship for an AE
after administration. This is far more difficult for the inter-
vention targeted by our review in postoperative patients
where the surgery and anaesthetic could all have contributed
to these events. The outcomes selected had been identified as
plausible concerns raised in the previously published litera-
ture on the safety of high FiO2.
8e10 Of note, the concerns raised
about harms resulting from high FiO2 are from animal studies,
case reports, or studies in other patient groups. For instance,
Hedenstierna and colleagues8 refer to animal studies where
70% oxygen resulted in the production of reactive oxygen
species in isolated rat lungs and lung injury was detected
within 24 h in live mice breathing 100% oxygen. High FiO2 can
increase peripheral vasoconstriction,50 and reduce cardiac
output51 and perfusion to the coronary, cerebral, renal, and
peripheral circulations.52e54 High FiO2 during anaesthesia is
also thought to be potentially associated with pulmonary
complications, such as atelectasis in humans,55 but there is no
published evidence apart from in live mice breathing 100%
O2.
56 The applicability and relevance of such data to periop-
erative hyperoxia in humans is unclear and our meta-analysis
did not demonstrate any consistent confirmatory evidence
behind purported AE on the cardiovascular or pulmonary
systems.Limitations
This review has some limitations. First, it was based pre-
dominantly on AE data from RCTs testing interventions based
on the administration of increased oxygen and only two
retrospective observational studies (judged to be at serious-
critical risk of bias)43,46 were available for inclusion. There
are obvious limitations to such data, particularly where AE are
not the primary focus of the study and may not be reliably
defined, monitored, or reported. Although the studies reported
on AE, this was not the primary aim of the data collection and
considerable outcome data were missing; thus, pooled esti-
mates were typically based only on a small fraction of the
entire dataset. Indeed, only two studies adequately specified
or defined pulmonary and cardiovascular AE.34,35 Second, it is
not possible to be sure that the absence of reported AE truly
means that these events did not occur and there may be un-
derlying reporting bias. Therefore, we cannot trust that ‘null’
findings amount to the same as actual absence of harm.57 A
further point to bear inmind iswhether perceived ‘null’ events
(safety) observed in participants taking part in RCTs can be
extrapolated reliably to real-life clinical practice. For instance
the findings from the trials cannot be applied to participants
with chronic lung disease or serious comorbidities, as these
322 - Mattishent et al.patients are typically excluded from trials. Third, we found
that there was significant statistical heterogeneity within
most of the analyses. Fourth, a substantial portion of the
included studies were based on subgroup or post hoc studies
that may carry a greater risk of bias. These include the possi-
bility of selective analysis and reporting of post hoc findings,
the use of subgroups, and difficulties in reliably measuring
long-term outcomes that had not been pre-specified in the
original trial. There is also the issue of bias arising from
competing risks, variations in co-interventions after comple-
tion of the trial, and differential attrition.Further research
Further research should focus on AE as the main predefined
outcome, with rigorous monitoring and transparent reporting.
Such studies could be registry-based (instead of randomised
trials) with long-term follow-up across several international
centres in order to capture a broader range of patients and
clinical situations. There should also be steps to address pro-
topathic bias and confounding by indication, and biases
potentially arising from lack of blinding.Conclusions
Our meta-analysis of several important outcomes did not
demonstrate any definite signal of harm with 80% FiO2
inspired oxygen. There is no substantive evidence of safety
concerns that would go against implementation of the WHO
and Centers for Disease Control and Prevention recommen-
dations on the use of high FiO2 to reduce SSI in intubated pa-
tients undergoing surgical procedures.Authors’ contributions
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